Inozyme Pharma Inc (INZY)

Jan 20, 2025

Inozyme Pharma, Inc. (NASDAQ:INZY) Short Interest Update - MarketBeat

Jan 20, 2025

Jan 19, 2025

Barclays PLC Increases Stock Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World

Jan 19, 2025

Jan 14, 2025

Inozyme Pharma (NASDAQ:INZY) Price Target Cut to $30.00 by Analysts at Piper Sandler - Defense World

Jan 14, 2025

Jan 14, 2025

Inozyme Pharma (NASDAQ:INZY) Price Target Lowered to $11.00 at Wells Fargo & Company - Defense World

Jan 14, 2025

Jan 13, 2025

Inozyme Pharma (NASDAQ:INZY) Given New $11.00 Price Target at Wells Fargo & Company - MarketBeat

Jan 13, 2025

Jan 13, 2025

Inozyme shares remain Outperform at Raymond James, target reduced amid study focus - Investing.com Australia

Jan 13, 2025

Jan 13, 2025

Inozyme shares remain Outperform at Raymond James, target reduced amid study focus By Investing.com - Investing.com South Africa

Jan 13, 2025

Jan 13, 2025

Inozyme Pharma (NASDAQ:INZY) Announces Positive Interim Data and Program Updates**SAN FRANCISCO, Jan 10, 2025 /PRNewswire/ — Inozyme Pharma, Inc. (NASDAQ:INZY) revealed favorable results from its recent interim data analysis and provided - Defense World

Jan 13, 2025

Jan 13, 2025

Seres Therapeutics Provides Corporate Updates and Financial Results - Defense World

Jan 13, 2025

Jan 13, 2025

HC Wainwright Predicts Inozyme Pharma Q1 Earnings - Defense World

Jan 13, 2025

Jan 13, 2025

HC Wainwright Comments on Inozyme Pharma Q1 Earnings - MarketBeat

Jan 13, 2025

Jan 12, 2025

Wedbush Reaffirms “Outperform” Rating for Inozyme Pharma (NASDAQ:INZY) - Defense World

Jan 12, 2025

Jan 12, 2025

HC Wainwright Forecasts Strong Price Appreciation for Inozyme Pharma (NASDAQ:INZY) Stock - Defense World

Jan 12, 2025

Jan 11, 2025

Inozyme Pharma stock hits 52-week low at $2.37 amid market challenges - Investing.com Canada

Jan 11, 2025

Jan 11, 2025

Analyzing Inozyme Pharma (NASDAQ:INZY) & Williston (OTCMKTS:WHCA) - Defense World

Jan 11, 2025

Jan 11, 2025

Inozyme Pharma Announces Positive Interim Data for INZ-701 - GlobeNewswire

Jan 11, 2025

Jan 10, 2025

Wedbush Reiterates "Outperform" Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat

Jan 10, 2025

Jan 10, 2025

Inozyme reports promising data on rare disease treatments By Investing.com - Investing.com Canada

Jan 10, 2025

Jan 10, 2025

Inozyme Pharma (NASDAQ:INZY) Price Target Raised to $16.00 - MarketBeat

Jan 10, 2025

Jan 10, 2025

Inozyme Pharma stock hits 52-week low at $2.37 amid market challenges By Investing.com - Investing.com South Africa

Jan 10, 2025

Jan 10, 2025

Inozyme reports promising data on rare disease treatments - Investing.com

Jan 10, 2025

Jan 10, 2025

Inozyme Pharma Advances with Promising Trial Results - TipRanks

Jan 10, 2025

Jan 10, 2025

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with - The Bakersfield Californian

Jan 10, 2025

Jan 10, 2025

Inozyme's INZ-701 Treatment Boosts Infant Survival Rate to 80% in ENPP1 Deficiency Trial - StockTitan

Jan 10, 2025

Jan 10, 2025

Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Jan 10, 2025

Jan 10, 2025

Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Jan 10, 2025

Jan 04, 2025

Barclays PLC Buys 55,497 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World

Jan 04, 2025

Jan 04, 2025

Geode Capital Management LLC Boosts Stake in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World

Jan 04, 2025

Dec 29, 2024

State Street Corp Acquires 50,386 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World

Dec 29, 2024

Dec 16, 2024

Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Dec 16, 2024

Dec 16, 2024

Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of “Buy” by Analysts - Defense World

Dec 16, 2024

Dec 14, 2024

Inozyme Pharma (NASDAQ:INZY) Coverage Initiated at Raymond James - Defense World

Dec 14, 2024

Dec 12, 2024

Raymond James Begins Coverage on Inozyme Pharma (NASDAQ:INZY) - MarketBeat

Dec 12, 2024

Dec 12, 2024

Jefferies initiates Buy rating on Inozyme Pharma stock, highlights potential of INZ-701 - Investing.com

Dec 12, 2024

Dec 09, 2024

Affinity Asset Advisors, LLC Increases Stake in Inozyme Pharma I - GuruFocus.com

Dec 09, 2024

Dec 06, 2024

Inozyme Pharma stock hits 52-week low at $2.53 amid market challenges - Investing.com Canada

Dec 06, 2024

Nov 30, 2024

Eventide Asset Management LLC Purchases 198,216 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat

Nov 30, 2024

Nov 27, 2024

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times

Nov 27, 2024

Nov 27, 2024

Inozyme Pharma to Present at Piper Sandler Healthcare Conference | INZY Stock News - StockTitan

Nov 27, 2024

Nov 27, 2024

Inozyme Pharma stock hits 52-week low at $2.6 amid market challenges - Investing.com Canada

Nov 27, 2024

Nov 22, 2024

Analyzing Inozyme Pharma (NASDAQ:INZY) and Theratechnologies (NASDAQ:THTX) - Defense World

Nov 22, 2024

Nov 20, 2024

Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks - MSN

Nov 20, 2024

Nov 17, 2024

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet? - Simply Wall St

Nov 17, 2024